Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Radiation Tolerance*; Bile Duct Neoplasms/*radiotherapy ; Bile Ducts, Intrahepatic/*pathology ; Cholangiocarcinoma/*radiotherapy ; Embolization, Therapeutic/*methods; Aged ; Algorithms ; Bile Duct Neoplasms/diagnosis ; Bile Duct Neoplasms/mortality ; Brachytherapy ; Cholangiocarcinoma/diagnosis ; Cholangiocarcinoma/mortality ; Female ; Humans ; Male ; Middle Aged ; Models, Theoretical ; Positron Emission Tomography Computed Tomography ; Radiotherapy Dosage ; Tomography, Emission-Computed, Single-Photon ; Treatment Outcome ; Yttrium Radioisotopes

Radioembolization is a valuable therapeutic option in patients with unresectable intrahepatic cholangiocarcinoma. The essential implementation of the absorbed dose calculation methods should take into account also the specific tumor radiosensitivity, expressed by the α parameter. Purpose of this study was to retrospectively calculate it in a series of patients with unresectable intrahepatic cholangiocarcinoma submitted to radioembolization. Twenty-one therapeutic procedures in 15 patients were analysed. Tumor absorbed doses were calculated processing the post-therapeutic ⁹⁰ Y-PET/CT images and the pre-treatment contrast-enhanced CT scans. Tumor absorbed dose and pre- and post-treatment tumor volumes were used to calculate α and α 3D parameters (dividing targeted liver in n voxels of the same volume with specific voxel absorbed dose). A tumor volume reduction was observed after treatment. The median of tumor average absorbed dose was 93 Gy (95% CI 81-119) and its correlation with the residual tumor mass was statistically significant. The median of α and α 3D parameters was 0.005 Gy ^-1 (95% CI 0.004-0.008) and 0.007 Gy ^-1 (95% CI 0.005-0.015), respectively. Multivariate analysis showed tumor volume and tumor absorbed dose as significant predictors of the time to tumor progression. The knowledge of radiobiological parameters gives the possibility to decide the administered activity in order to improve the outcome of the treatment.
(© 2021. The Author(s).)

JAMA Oncol. 2020 Jan 1;6(1):51-59. (PMID: 31670746)
Phys Med Biol. 2018 Dec 19;64(1):01TR01. (PMID: 30523903)
Nucl Med Biol. 2015 Jan;42(1):59-64. (PMID: 25213104)
Acta Oncol. 1999;38(7):883-93. (PMID: 10606418)
J Vasc Interv Radiol. 2014 Feb;25(2):288-95. (PMID: 24269792)
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1696. (PMID: 19618182)
J Vasc Interv Radiol. 2013 Aug;24(8):1153-5. (PMID: 23885913)
Eur J Nucl Med. 1996 Aug;23(8):947-52. (PMID: 8753684)
Cardiovasc Intervent Radiol. 2013 Apr;36(2):440-8. (PMID: 22956045)
J Vasc Interv Radiol. 2013 Aug;24(8):1227-34. (PMID: 23602420)
J Vasc Interv Radiol. 2014 Feb;25(2):256-65. (PMID: 24461131)
Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1718-1738. (PMID: 26112387)
Radiat Oncol. 2018 May 16;13(1):96. (PMID: 29769103)
J Nucl Med. 2010 Sep;51(9):1377-85. (PMID: 20720056)
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):900-7. (PMID: 18262101)
Ann Surg Oncol. 2013 Nov;20(12):3779-86. (PMID: 23846786)
Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1393-406. (PMID: 21494856)
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1185-1193. (PMID: 28197686)
Front Oncol. 2014 Aug 19;4:210. (PMID: 25191640)
J Cancer Res Clin Oncol. 2017 Mar;143(3):481-489. (PMID: 27826686)
J Vasc Interv Radiol. 2018 Aug;29(8):1101-1108. (PMID: 30042074)
Cardiovasc Intervent Radiol. 2020 Sep;43(9):1305-1314. (PMID: 32642986)
Br J Cancer. 2016 Jul 26;115(3):297-302. (PMID: 27336601)
EJNMMI Phys. 2018 Nov 2;5(1):22. (PMID: 30386924)
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):669-676. (PMID: 30374530)
Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1037-45. (PMID: 21308371)
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2270-2279. (PMID: 31324943)
Ann Surg Oncol. 2010 Feb;17(2):484-91. (PMID: 19876691)
Br J Radiol. 2016 Jun;89(1062):20150943. (PMID: 26943239)
Lancet Oncol. 2017 Nov;18(11):e636. (PMID: 29208390)
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1783-1786. (PMID: 28536834)
Hepatology. 2017 Sep;66(3):969-982. (PMID: 28407278)
Liver Transpl. 2002 Mar;8(3):233-40. (PMID: 11910568)
EJNMMI Res. 2013 Jul 25;3(1):57. (PMID: 23885971)
Cardiovasc Intervent Radiol. 2012 Feb;35(1):105-16. (PMID: 21431970)

0 (Yttrium Radioisotopes)
1K8M7UR6O1 (Yttrium-90)

Date Created: 20211006 Date Completed: 20211230 Latest Revision: 20211230

20250114

PMC8492793

10.1038/s41598-021-99219-7

34611210